Obesity-drug developer BioAge Labs Inc. gained about 20% after its initial public offering on Thursday, while natural-gas ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

Soaring demand for weight-loss drugs, expected to be a $150 billion market by early 2030s, has attracted more investors toward companies tapping into the lucrative market. The debut valued BioAge at ...

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...